FDA Approved: BALVERSA — Supplemental Application (Janssen Products LP)

View source ↗

Summary

The FDA approved a supplemental application for BALVERSA (erdafitinib) from Janssen Products LP, resulting in labeling changes (potentially expanded indication)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• BALVERSA (erdafitinib)

Snippet

SUPPL AP for BALVERSA (ERDAFITINIB)